Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Clinical Epigenetics|April 5, 2016
Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancerSøren Kristiansen, Dorte Nielsen, György Sölétormos
Critical Reviews in Clinical Laboratory Sciences|March 12, 2014
Methylated DNA for monitoring tumor growth and regression: how do we get there?Søren Kristiansen, Dorte Nielsen, György Sölétormos
Cancer Treatment Reviews|July 21, 2019
Checkpoint inhibitors in pancreatic cancerAndreas Henriksen, Anne Dyhl-Polk, Inna Chen, et al.
Acta Oncologica (Stockholm, Sweden)|November 24, 2017
Triple negative breast cancer - prognostic role of immune-related factors: a systematic reviewElisabeth Specht Stovgaard, Dorte Nielsen, Estrid Hogdall, et al.
BMJ Case Reports|June 3, 2016
5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRIYama Fakhri, Morten Dalsgaard, Dorte Nielsen, et al.
Cancer Treatment Reviews|December 30, 2017
Checkpoint inhibitors in breast cancer - Current statusAnne Polk, Inge-Marie Svane, Michael Andersson, et al.
Oncology|September 21, 2017
Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II StudyFinn Ole Larsen, Alice Markussen, Laura V Diness, et al.
Cancer Chemotherapy and Pharmacology|July 11, 2002
Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cellsDorte Nielsen, Jens Eriksen, Christian Maare, et al.
Non-Coding RNA|April 17, 2018
Circulating microRNAs as Prognostic and Predictive Biomarkers in Patients with Colorectal CancerJakob Vasehus Schou, Julia Sidenius Johansen, Dorte Nielsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2013
Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximabKristin Skougaard, Dorte Nielsen, Benny Vittrup Jensen, et al.
Pageof 9